Xiao Hui Gu
Plus aucun poste en cours
Historique de carrière de Xiao Hui Gu
Anciens postes connus de Xiao Hui Gu
Sociétés | Poste | Début | Fin |
---|---|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01/01/2008 | 01/01/2008 |
EXELIXIS, INC. | Corporate Officer/Principal | - | - |
PHARMARON BEIJING CO., LTD. | Corporate Officer/Principal | 01/05/2011 | - |
Formation de Xiao Hui Gu
Hunan Normal University | Undergraduate Degree |
Shanghai Institute of Organic Chemistry | Doctorate Degree |
Statistiques
Internationale
Chine | 4 |
Etats-Unis | 3 |
Opérationnelle
Corporate Officer/Principal | 3 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectorielle
Commercial Services | 3 |
Consumer Services | 3 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
PHARMARON BEIJING CO., LTD. | Commercial Services |
EXELIXIS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Bourse
- Insiders
- Xiao Hui Gu
- Expérience